Seres Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Seres Therapeutics
MCRB Stock  USD 0.86  0.05  6.17%   
Seres Therapeutics financial statements provide useful quarterly and yearly information to potential Seres Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Seres Therapeutics financial statements helps investors assess Seres Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Seres Therapeutics' valuation are summarized below:
Gross Profit
23.3 M
Profit Margin
(0.20)
Market Capitalization
137.5 M
Enterprise Value Revenue
1.3002
Revenue
126.3 M
We have found one hundred twenty available fundamental trend indicators for Seres Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Seres Therapeutics current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of January 30, 2025, Market Cap is expected to decline to about 195.8 M. In addition to that, Enterprise Value is expected to decline to about 289.7 M

Seres Therapeutics Total Revenue

152.54 Million

Check Seres Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Seres Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.1 M, Interest Expense of 15.9 M or Selling General Administrative of 106 M, as well as many indicators such as Price To Sales Ratio of 1.21, Dividend Yield of 0.0 or Days Sales Outstanding of 39.22. Seres financial statements analysis is a perfect complement when working with Seres Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Seres Therapeutics Correlation against competitors.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

Seres Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets225.8 M412.4 M194.7 M
Slightly volatile
Other Current Liabilities97.3 M92.7 M28.9 M
Slightly volatile
Total Current Liabilities119.1 M113.5 M44.6 M
Slightly volatile
Property Plant And Equipment Net159.7 M152.1 M48.3 M
Slightly volatile
Accounts Payable6.7 M4.2 M5.2 M
Slightly volatile
Cash93.9 M147.2 M79.9 M
Slightly volatile
Non Current Assets Total221.2 M210.7 M67.3 M
Slightly volatile
Other Assets24.2 M23.1 M10.7 M
Slightly volatile
Cash And Short Term Investments156.3 M147.2 M126.3 M
Slightly volatile
Common Stock Shares Outstanding154.6 M147.2 M64.5 M
Slightly volatile
Other Current Assets10.4 M10.5 M8.4 M
Slightly volatile
Total Liabilities487.2 M464 M179.5 M
Slightly volatile
Total Current Assets166.7 M201.7 M137.5 M
Slightly volatile
Common Stock163 K155.2 K64.1 K
Slightly volatile
Short and Long Term Debt Total258.3 M246 M66.2 M
Slightly volatile
Other Liabilities78 M108 M61.8 M
Slightly volatile
Current Deferred Revenue13.6 M8.9 M9.9 M
Slightly volatile
Common Stock Total Equity150.9 K143.8 K62 K
Slightly volatile
Liabilities And Stockholders Equity245.7 M412.4 M195.1 M
Slightly volatile
Non Current Liabilities Total368 M350.5 M137.2 M
Slightly volatile
Property Plant And Equipment Gross221.4 M210.9 M59.1 M
Slightly volatile
Short Term Debt7.1 M7.7 M5.5 M
Slightly volatile
Property Plant Equipment21.7 M26.4 M16.8 M
Slightly volatile
Short and Long Term Debt562.7 K410.4 K691.6 K
Slightly volatile
Capital Surpluse552.2 M1 B493.1 M
Slightly volatile
Non Current Liabilities Other1.8 M1.9 M53.8 M
Slightly volatile
Capital Lease Obligations135.7 M129.3 M39.3 M
Slightly volatile
Net Working Capital134.8 M88.3 M121.6 M
Very volatile
Capital Stock101.6 K155.2 K71.2 K
Slightly volatile
Long Term Debt Total34.2 M58.2 M30.6 M
Slightly volatile

Seres Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization6.1 M7.2 M5 M
Slightly volatile
Selling General Administrative106 M100.9 M39 M
Slightly volatile
Other Operating Expenses282.9 M269.5 M120.5 M
Slightly volatile
Research Development87.5 M167.7 M75.9 M
Slightly volatile
Total Operating Expenses282.1 M268.6 M120.3 M
Slightly volatile
Cost Of Revenue601.9 K633.6 K31.1 M
Very volatile
Interest Income8.1 M7.8 M2.5 M
Slightly volatile
Non Operating Income Net Other1.6 M2.7 M1.3 M
Slightly volatile
Reconciled Depreciation5.5 M5.6 M6.9 M
Slightly volatile
Non Recurring1.2 M1.3 M1.5 M
Slightly volatile

Seres Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation41.2 M39.2 M15 M
Slightly volatile
Begin Period Cash Flow206.7 M196.9 M82.3 M
Slightly volatile
Other Cashflows From Financing Activities2.6 M2.7 M23.4 M
Pretty Stable
Depreciation4.9 M7.2 M4.1 M
Slightly volatile
Capital Expenditures5.8 M9.2 M4.9 M
Slightly volatile
Total Cash From Financing Activities79.4 M82.5 M65.5 M
Slightly volatile
End Period Cash Flow96.2 M156.6 M82.1 M
Slightly volatile
Change To Netincome16.2 M29.3 M13.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.211.2819.0479
Very volatile
Days Sales Outstanding39.2222.5626.8088
Slightly volatile
Stock Based Compensation To Revenue0.230.240.7195
Very volatile
Capex To Depreciation1.41.473.8586
Slightly volatile
EV To Sales1.791.8917.819
Very volatile
Payables Turnover0.210.226.4501
Pretty Stable
Sales General And Administrative To Revenue0.590.631.745
Pretty Stable
Research And Ddevelopement To Revenue0.991.044.1263
Very volatile
Capex To Revenue0.0690.07260.5513
Slightly volatile
Cash Per Share1.091.152.3194
Very volatile
Days Payables Outstanding1.1 K1.7 K1.1 K
Slightly volatile
Current Ratio1.942.0411.3488
Slightly volatile
Receivables Turnover13.7316.7516.9384
Slightly volatile
Graham Number2.893.045.4005
Very volatile
Capex Per Share0.110.07160.0896
Very volatile
Revenue Per Share0.570.890.6519
Pretty Stable
Interest Debt Per Share1.681.60.5948
Slightly volatile
Debt To Assets0.560.540.284
Slightly volatile
Days Of Payables Outstanding1.1 K1.7 K1.1 K
Slightly volatile
Ebt Per Ebit1.111.211.0345
Slightly volatile
Quick Ratio1.611.711.3285
Slightly volatile
Net Income Per E B T0.770.910.9224
Very volatile
Cash Ratio1.421.499.5406
Slightly volatile
Days Of Sales Outstanding39.2222.5626.8088
Slightly volatile
Fixed Asset Turnover1.020.860.9832
Slightly volatile
Debt Ratio0.560.540.284
Slightly volatile
Price Sales Ratio1.211.2819.0479
Very volatile
Asset Turnover0.160.320.1613
Slightly volatile

Seres Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap195.8 M206.1 M721.5 M
Slightly volatile
Enterprise Value289.7 M305 M692.2 M
Slightly volatile

Seres Fundamental Market Drivers

Cash And Short Term Investments128 M

Seres Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Seres Therapeutics Financial Statements

Seres Therapeutics stakeholders use historical fundamental indicators, such as Seres Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Seres Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Seres Therapeutics' assets and liabilities are reflected in the revenues and expenses on Seres Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Seres Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue8.9 M13.6 M
Total Revenue145.3 M152.5 M
Cost Of Revenue633.6 K601.9 K
Stock Based Compensation To Revenue 0.24  0.23 
Sales General And Administrative To Revenue 0.63  0.59 
Research And Ddevelopement To Revenue 1.04  0.99 
Capex To Revenue 0.07  0.07 
Revenue Per Share 0.89  0.57 
Ebit Per Revenue(0.98)(1.03)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FFord Motor
GMGeneral Motors
SSentinelOne
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:
How To Invest In Seres
Details
Is Seres Stock a good investment?
Details
What is Seres Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Seres Therapeutics Correlation against competitors.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.40)
Revenue Per Share
0.871
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.1)
Return On Equity
(15.56)
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY